Business Context and Reporting Period
This Form 8-K Current Report for IMMUNIC, INC. covers events occurring on December 29, 2025. The filing details significant executive employment agreements and organizational changes following the recent incorporation of Gliomic Therapeutics Inc., a wholly-owned Delaware subsidiary.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or liquidity metrics. It focuses exclusively on executive compensation terms and employment structures.
- Dr. Duane Nash (Executive Chairman): Monthly base salary of $33,987 as CEO/President of Gliomic (effective Jan 1, 2026). No additional cash retainer for Board service during the employment term.
- Dr. Daniel Vitt (CEO): Annual base salary of $305,000 with a target bonus of 55% of salary. Entitled to up to $50,000 in U.S. housing expense reimbursement.
- Dr. Daniel Vitt (Immunic AG): Fixed annual salary of €282,826.50 and variable remuneration up to €155,786.50 based on targets.
Material Changes
The filing reports the following material changes to executive roles and compensation:
- Role Transition for Dr. Nash: Dr. Nash's previous agreement as Executive Chairman expired on December 31, 2025. He will transition to CEO and President of the new subsidiary, Gliomic, effective January 1, 2026.
- Split Duties for Dr. Vitt: Dr. Vitt will split his working time 50/50 between the U.S. parent company (Immunic, Inc.) and the German subsidiary (Immunic AG). This arrangement replaces a previously suspended service agreement with Immunic AG.
- Compensation Structure: New agreements formalize salary, bonus targets, and expense reimbursements for both executives, subject to the Company's clawback policy.
Outlook, Risks, and Contingencies
Management Commentary: The agreements reflect a strategic restructuring to align executive leadership with the new subsidiary, Gliomic, and to formalize the dual-residence operational model for the CEO.
Termination Provisions:
- Dr. Nash: Upon termination, he is entitled to unpaid salary, six months of COBRA reimbursement, and accrued benefits. He will resume receiving a cash retainer for Board service post-termination.
- Dr. Vitt: Employment continues until reappointment to the Immunic AG Management Board on a full-time basis or termination.
Risks: The filing notes that certain compensation is subject to clawback policies. No specific financial risks or contingencies regarding the company's operations are disclosed in this document.
Investor Verification Checklist
- Verify the operational status and strategic purpose of the newly incorporated subsidiary, Gliomic Therapeutics Inc.
- Review the full text of the Nash Agreement (Exhibit 10.1) and New Employment Agreement (Exhibit 10.2) for detailed termination triggers and equity award specifics.
- Confirm the impact of Dr. Vitt's 50/50 time split on the oversight of U.S. versus German operations.
- Monitor future filings for the formal reappointment of Dr. Vitt to the Immunic AG Management Board on a full-time basis.